美國注意力不足過動症市場規模、佔有率和趨勢分析報告：按藥物類型、人口統計、分銷管道和細分市場預測，2025 年至 2033 年

美國注意力不足過動症市場摘要

美國注意力不足過動症市場規模預計在 2024 年為 103.1 億美元，預計到 2033 年將達到 138.8 億美元，2025 年至 2033 年的複合年成長率為 3.3%。該市場的主要驅動力是診斷病例的持續增加，這得益於診斷標準的擴大、公眾意識的提高以及初級保健篩檢一致性的提高。

注意力不足過動症(ADHD) 仍然是美國最常見的神經發育障礙之一，影響著臨床實踐和公共衛生舉措。 2020-2022 年全國健康訪問調查報告顯示，11.3% 的 5-17 歲美國兒童曾被診斷為 ADHD。男孩（14.5%）被診斷的可能性大約是女孩（8.0%）的兩倍。成年人也觀察到了類似的趨勢，18-44 歲族群中 ADHD 的終生盛行率估計約為 8.1%。

在學校篩檢計畫和放鬆管制措施的推動下，看護者和教育工作者的意識不斷增強，確診者人數正在進一步擴大。治療方案的創新也是美國注意力不足過動症)產業成長的主要驅動力。儘管哌甲酯和安非他命非他明等興奮劑仍佔據處方藥的主導地位，但近期的進展凸顯了市場向非興奮劑和數位療法的轉變。 2023年12月，FDA 將首個基於遊戲的數位療法 EndeavorRx 的適應症擴展至13-17歲的青少年，此前關鍵的 STARS-ADHD 試驗數據顯示，經 ToVa 評估，該療法顯著改善了患者的注意力（p<0.0001）。

醫療服務提供和付款人政策的變化持續影響著市場動態。遠端醫療的廣泛應用因 COVID-19 疫情而加速，透過促進更頻繁的後續觀察和劑量調整，正在減少持續照護的障礙。此外，更新後的保險覆蓋指南現在允許將數位和行為療法與藥物治療一起納入承保範圍。特別是隨著人們越來越關注焦慮症和學習障礙等合併症，將行為療法與藥物管理相結合的綜合護理模式在兒科和青少年醫療保健網路中變得越來越突出。 2025 年 1 月，Supernus Pharmaceuticals 獲得了 FDA 對 Qelbree 的標籤更新，增加了針對哺乳婦女的新動態數據和資訊。

過動症 (ADHD) 領域的併購交易相對謹慎，主要涉及尋求擴大治療和數位健康產品組合的專業製藥公司。 2024 年 9 月，Collegium Pharmaceuticals 收購了 Ironshore Therapeutics。透過此次收購，Collegium Pharmaceuticals 擴大了其在神經病學領域，尤其是過動症 (ADHD) 市場的影響力，並將 ADHD 治療藥物 Jornay PM 納入其產品組合。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國注意力不足過動症市場變數、趨勢與範圍

• 市場體系展望
  • 母市場展望
  • 相關/輔助市場展望
• 市場動態
  • 市場促進因素分析
  • 市場限制因素分析
• 美國注意力不足過動症（ADHD）市場分析工具
  • 產業分析-波特五力分析
  • PESTEL分析
• 美國注意力不足過動症（ADHD）市場：通路分析

第4章美國注意力不足過動症市場：藥物類型估計與趨勢分析

• 藥品類型細分儀表板
• 美國注意力不足過動症（ADHD）市場：按藥物類型進行的變化分析
• 美國注意力不足過動症(ADHD) 市場規模及趨勢分析（依藥物類型），2021 年至 2033 年
• 興奮劑
  • 安非他命
  • 哌甲酯
  • Lisdexamfetamine
  • 右哌甲酯
• 無刺激性
  • 阿托西汀
  • 胍法辛
  • 可樂定
  • 其他

第5章美國注意力不足過動症市場：人口統計估計與趨勢分析

• 人口統計細分儀表板
• 美國注意力不足過動症（ADHD）市場：人口變化分析
• 美國注意力不足過動症(ADHD) 市場規模及趨勢分析（依人口統計），2021 年至 2033 年
• 孩子
• 成人

第6章美國注意力不足過動症市場：通路評估與趨勢分析

• 分銷通路細分儀表板
• 美國注意力不足過動症（ADHD）市場：分銷管道差異分析
• 美國注意力不足過動症(ADHD) 市場規模及趨勢分析（按分銷管道），2021 年至 2033 年
• 零售藥局
• 醫院藥房

第7章 競爭態勢

• 主要市場參與企業的近期趨勢和影響分析
• 公司/競爭對手分類
• 供應商格局
  • Key company heat map analysis, 2024
• 公司簡介
  • Lilly.
  • Pfizer Inc.
  • Johnson &Johnson
  • Lupin Pharmaceuticals, Inc.
  • Novartis Pharmaceuticals Corporation
  • Takeda Pharmaceutical Company Limited.
  • Mallinckrodt.
  • PURDUE PHARMA LP
  • NEOS THERAPEUTICS, INC.
  • Supernus Pharmaceuticals, Inc.

U.S. Attention Deficit Hyperactivity Disorder Market Summary

The U.S. attention deficit hyperactivity disorder market size was estimated at USD 10.31 billion in 2024 and is projected to reach USD 13.88 billion by 2033, growing at a CAGR of 3.3% from 2025 to 2033. The market is primarily driven by a continuous increase in diagnosed cases, supported by expanded diagnostic criteria, greater public awareness, and more consistent screening in primary care settings.

Attention Deficit Hyperactivity Disorder (ADHD) remains one of the most commonly diagnosed neurodevelopmental disorders in the U.S., shaping clinical practice and public health initiatives. A 2020-2022 National Health Interview Survey reported that 11.3% of U.S. children aged 5 to 17 have been diagnosed with ADHD at some point. Boys (14.5%) are nearly twice as likely as girls (8.0%) to receive a diagnosis. Similar trends are seen in adults, with lifetime ADHD prevalence estimated at around 8.1% among those aged 18 to 44.

Growing awareness among caregivers and educators, driven by school screening programs and destigmatization efforts, is further expanding the pool of patients being identified. Innovation in treatment options is another major driver of growth of the U.S. attention deficit hyperactivity disorder industry. Although stimulant medications such as methylphenidate and amphetamines continue to dominate prescriptions, recent advances highlight the market's shift toward non-stimulant and digital therapies. In December 2023, the FDA expanded the indication for EndeavorRx, the first game-based digital therapeutic, to include adolescents aged 13 to 17, following pivotal STARS-ADHD trial data showing significant attention improvements on TOVA assessments (p < 0.0001).

Changes in care delivery and payer policies continue to influence market dynamics. The widespread adoption of telehealth, accelerated by the COVID-19 pandemic, has reduced barriers to ongoing treatment by facilitating more frequent follow-ups and dose adjustments. In addition, updated insurance coverage guidelines now commonly reimburse digital and behavioral therapies alongside medication. Integrated care models that combine behavioral therapy with medication management within pediatric and adolescent health networks are becoming increasingly prominent, especially as comorbid conditions such as anxiety and learning disorders receive greater attention. In January 2025, Supernus Pharmaceuticals obtained an FDA label update for Qelbree, adding new pharmacodynamic data and information on breastfeeding women.

M&A activity in the ADHD segment is relatively selective, primarily involving specialty pharmaceutical companies aiming to broaden their therapeutic or digital health portfolios. In September 2024, Collegium Pharmaceutical acquired Ironshore Therapeutics. The deal expanded Collegium's reach in the neurology sector, specifically in the ADHD market, and added Jornay PM, a stimulant to treat ADHD, to its portfolio.

U.S. Attention Deficit Hyperactivity Disorder Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. attention deficit hyperactivity disorder market report based on drug type, demographics, and distribution channel:

• Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
• Stimulants
• Amphetamine
• Methylphenidate
• Lisdexamfetamine
• Dexmethylphenidate
• Non-stimulants
• Atomoxetine
• Guanfacine
• Clonidine
• Others
• Demographics Outlook (Revenue, USD Million, 2021 - 2033)
• Children
• Adults
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Retail Pharmacy
• Hospital Pharmacy

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Type
  • 1.2.2. Demographics
  • 1.2.3. Distribution Channel
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Type Outlook
  • 2.2.2. Demographics Outlook
  • 2.2.3. Distribution Channel Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Attention Deficit Hyperactivity Disorder Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. U.S. Attention Deficit Hyperactivity Disorder Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political Landscape
    • 3.3.2.2. Technological Landscape
    • 3.3.2.3. Economic Landscape
• 3.4. U.S. Attention Deficit Hyperactivity Disorder Market: Pipeline Analysis

Chapter 4. U.S. Attention Deficit Hyperactivity Disorder Market: Drug Type Estimates & Trend Analysis

• 4.1. Drug Type Segment Dashboard
• 4.2. U.S. Attention Deficit Hyperactivity Disorder Market: Drug Type Movement Analysis
• 4.3. U.S. Attention Deficit Hyperactivity Disorder Market Size & Trend Analysis, by Drug Type, 2021 - 2033 (USD Million)
• 4.4. Stimulants
  • 4.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.4.2. Amphetamine
    • 4.4.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.4.3. Methylphenidate
    • 4.4.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.4.4. Lisdexamfetamine
    • 4.4.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.4.5. Dexmethylphenidate
    • 4.4.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 4.5. Non-stimulants
  • 4.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.5.2. Atomoxetine
    • 4.5.2.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.5.3. Guanfacine
    • 4.5.3.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.5.4. Clonidine
    • 4.5.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
  • 4.5.5. Others
    • 4.5.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 5. U.S. Attention Deficit Hyperactivity Disorder Market: Demographics Estimates & Trend Analysis

• 5.1. Demographics Segment Dashboard
• 5.2. U.S. Attention Deficit Hyperactivity Disorder Market: Demographics Movement Analysis
• 5.3. U.S. Attention Deficit Hyperactivity Disorder Market Size & Trend Analysis, by Demographics, 2021 - 2033 (USD Million)
• 5.4. Children
  • 5.4.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)
• 5.5. Adults
  • 5.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 6. U.S. Attention Deficit Hyperactivity Disorder Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Distribution Channel Segment Dashboard
• 6.2. U.S. Attention Deficit Hyperactivity Disorder Market: Distribution Channel Movement Analysis
• 6.3. U.S. Attention Deficit Hyperactivity Disorder Market Size & Trend Analysis, by Distribution Channel, 2021 - 2033 (USD Million)
• 6.4. Retail Pharmacy
  • 6.4.1. Market Estimates and Forecasts 2021 - 2033 (USD million)
• 6.5. Hospital Pharmacy
  • 6.5.1. Market Estimates and Forecasts 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company heat map analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. Lilly.
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Pfizer Inc.
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Johnson & Johnson
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Lupin Pharmaceuticals, Inc.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Novartis Pharmaceuticals Corporation
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Takeda Pharmaceutical Company Limited.
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Mallinckrodt.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. PURDUE PHARMA L.P.
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. NEOS THERAPEUTICS, INC.
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Supernus Pharmaceuticals, Inc.
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. attention deficit hyperactivity disorder market, by drug type, 2021 - 2033 (USD Million)
• Table 3 U.S. attention deficit hyperactivity disorder market, by demographics, 2021 - 2033 (USD Million)
• Table 4 U.S. attention deficit hyperactivity disorder market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. attention deficit hyperactivity disorder market: market outlook
• Fig. 10 U.S. androgenetic alopecia competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. attention deficit hyperactivity disorder market driver impact
• Fig. 16 U.S. attention deficit hyperactivity disorder market restraint impact
• Fig. 17 U.S. Attention deficit hyperactivity disorder market strategic initiatives analysis
• Fig. 18 U.S. attention deficit hyperactivity disorder market: drug type movement analysis
• Fig. 19 U.S. attention deficit hyperactivity disorder market: drug type outlook and key takeaways
• Fig. 20 Stimulants market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 21 Amphetamine estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 22 Methylphenidate estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 23 Lisdexamfetamine estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 24 Dexmethylphenidate estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 25 Non-stimulants market estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 26 Atomoxetine estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 27 Guanfacine estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 28 Clonidine estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 29 Others estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 30 U.S. attention deficit hyperactivity disorder market: demographics movement analysis
• Fig. 31 U.S. attention deficit hyperactivity disorder market: demographics outlook and key takeaways
• Fig. 32 Children (2-17 years) estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 33 Adults estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 34 Others estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 35 U.S. attention deficit hyperactivity disorder market: distribution channel movement analysis
• Fig. 36 U.S. attention deficit hyperactivity disorder market: distribution channel outlook and key takeaways
• Fig. 37 Hospital pharmacy estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 38 Retail pharmacy estimates and forecast, 2021 - 2033 (USD Million)
• Fig. 39 Others estimates and forecast, 2021 - 2033 (USD Million)